StemCells Inc. (STEM) Partners With R Biomedical to Develop and Commercialize Reagents for Human iPS Cell Research  
10/30/2012 7:05:41 AM

NEWARK, Calif., Oct. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has partnered with R Biomedical, an Edinburgh, UK-based biomedical company, to develop and commercialize a range of cell lines and reagents to facilitate human induced pluripotent stem (iPS) cell-based research for regenerative medicine applications. The first product under the partnership, an "ultra-primary" human fibroblast cell line from which researchers can generate iPS cell lines, was launched today under the SC Proven brand.